
Ready to start planning your care? Call us at  $\underline{800-525-2225}$  to make an appointment.  $\times$ 



Memorial Sloan Kettering Cancer Center



NOVE & WARTPHARMACOLOGY PROGRAM

# The David Scheinberg Lab

Molecular Pharmacology Program

# Research



David A. Scheinberg, MD, PhD Chair, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery

The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, engineered cells, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. Examples include a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in Phase II human trials (*Blood*, 2010), and a vaccine to WT1 in Phase III trials. Read full article in <u>Science</u>.

We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, humanized antibodies, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular

proteins (*Science Trans. Med., 2013*), (*Nature Biotech.*, 2015), as well as prototype targeted nano-machines (*Nature Nano, 2013*), and cellular micropharmacies (*Nature Chem.Biol., 2021*).

### **Research Projects**

#### **Projects**



## **Featured News**



### At Work: Center for Experimental Therapeutics Chair David Scheinberg

A second-generation physician-scientist, David Scheinberg specializes in caring for patients with leukemia — and developing new ways to treat it.

#### ANNOUNCEMENT



#### Innovative Partnership Will Speed Drug Discovery and Development

Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients.

#### Scientists ID Antibody That Might Boost Cancer Therapy

Physician-scientist David Scheinberg discussed his discovery of a unique monoclonal antibody, a molecule that can be engineered to target specific prot...

View All Featured News

# **Publications Highlights**

Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O'Reilly RJ, Liu C, Scheinberg DA. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Science translational medicine. 2013;5(176):176ra33. Doi: 10.1126/scitranslmed.3005661. PubMed. PMCID: PMC3963696.

Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, O'Reilly RJ, Scheinberg DA. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nature biotechnology. 2015;33(10):1079-86. Doi: 10.1038/nbt.3349. PubMed PMID: 26389576; PMCID: PMC4600043.

**View All Publications** 

People

# David A. Scheinberg, MD, PhD

Chair, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery Molecular Pharmacology Program Member David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy. MD, PhD, Johns Hopkins University School of Medicine

### Email Address

#### 646-888-2190 Office Phone


scheinbd@

View physician profile Physician profile

#### Members




Research Assistant





Dao



KOTOTILSVIL

Research Assistant



IVICDEVILL

Laboratory Member

Samarah Forbes

Senior Administrative Assistant Zita Aretz Graduate Student

#### Winson Cai

Graduate Student

Annelisa Cornel Research Fellow



Josh Jaeyop Lee Hematology/Oncology Fellow



Qianqian (Skylar) Lin Graduate Student



Manish Malviya Senior Research Scientist



Jeremy P. Meyerberg Research Technician




Stephanie Pierre Graduate Student



Sarah Qureshy Medical Student Research Fellow Education



Ekaterina Revskaya Senior Research Scientist



Kristen Vogt Graduate Student



Patrick Wallisch Graduate Student

Lab Alumni +

Lab Affiliations +

Lab News & Events

Journal Club & Photo Album

# Get in Touch

<u>scheinbd@mskcc.org</u>
Lab Head Email

646-888-2190 Office Phone

<u>646-888-2205</u> Lab Phone

Lab Resources +

# Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report ("disclose") the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

David A. Scheinberg discloses the following relationships and financial interests:

Actinium Equity; Intellectual Property Rights; Professional Services and Activities Arvinas, Inc. Equity Atengen, Inc. Equity; Professional Services and Activities (Uncompensated) Bridge Medicines Professional Services and Activities (Uncompensated) Colmmune, Inc. Equity; Intellectual Property Rights; Professional Services and Activities Eureka Therapeutics Inc Equity; Professional Services and Activities Great Point Partners Equity; Professional Services and Activities

Iovance Biotherapeutics, Inc. Equity Lantheus Medical Imaging, Inc. Equity OncoPep, Inc. Professional Services and Activities Pfizer, Inc. Equity; Professional Services and Activities Repertoire Immune Medicines, Inc. Professional Services and Activities Sapience Therapeutics, Inc. Equity; Fiduciary Role / Position Sellas Life Science Group Equity; Fiduciary Role / Position; Intellectual Property Rights

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies <u>here</u>. For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at <u>ecoi@mskcc.org</u>.

View all disclosures

About Us			
<u>Overview</u>			
Leadership			
Administration			
<u>History</u>			
Contact Us			
-			
Research			

#### <u>Overview</u>

Research programs

Research labs

Core facilities & resources

#### Education & Training

<u>Overview</u>

Postdoctoral training

Gerstner Sloan Kettering Graduate School

Joint graduate programs

Programs for college & high school students

#### News & Events

<u>Overview</u>

Seminars & events

#### **Open Positions**

<u>Overview</u>

Faculty positions

Postdoctoral positions

Communication preferences Cookie preferences Legal disclaimer Accessibility Statement Privacy policy Public notices © 2024 Memorial Sloan Kettering Cancer Center